Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy

Mark H. Einstein, Katherine M. Smith, Thomas E. Davis, Kathleen M. Schmeler, Daron Gale Ferris, Ashlyn H. Savage, Jermaine E. Gray, Mark H. Stoler, Thomas C. Wright, Alex Ferenczy, Philip E. Castle

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

High-risk human papillomavirus (hrHPV) testing is now being introduced as a potential primary screening test for improved detection of cervical precancer and cancer. Current U.S. Food and Drug Administration-approved tests are batch tests that take several hours to complete. A rapid, non-batch test might permit point-of-care (POC) testing, which can facilitate same-day screen and management strategies. For a non-batch, random-access platform (GeneXpert; Cepheid, Sunnyvale, CA), a prototype hrHPV assay (Xpert) has been developed where testing for 14 hrHPV types can be completed in 1 h. In the first clinical evaluation, Xpert was compared to two validated hrHPV tests, the cobas HPV test (cobas, Roche Molecular Systems) and Hybrid Capture 2 (hc2, Qiagen), and to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in the United States (n = 697). The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) (n = 141) was equal to that of cobas (90.8% versus 90.8%, P = 1) and greater than that of hc2 (90.8% versus 81.6%, P =0.004). Xpert was more specific than cobas (42.6% versus 39.6%, P = 0.02) and less specific than hc2 (42.6% versus 47.7%, P<0.001). Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CIN3+) (n = 91). HPV16 detection by Xpert identified 41.8% of the CIN2+specimens with a positive predictive value (PPV) of 54.6%. By comparison, HPV16 detection by cobas identified 42.6% of the CIN2+specimens with a PPV of 55.0%. hrHPV detection by the Xpert demonstrated excellent clinical performance for identifying women with CIN2+and CIN3+that was comparable to that of currently available clinically validated tests.

Original languageEnglish (US)
Pages (from-to)2089-2095
Number of pages7
JournalJournal of clinical microbiology
Volume52
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Colposcopy
Cervical Intraepithelial Neoplasia
United States Food and Drug Administration
Uterine Cervical Neoplasms
Referral and Consultation
Population

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. / Einstein, Mark H.; Smith, Katherine M.; Davis, Thomas E.; Schmeler, Kathleen M.; Ferris, Daron Gale; Savage, Ashlyn H.; Gray, Jermaine E.; Stoler, Mark H.; Wright, Thomas C.; Ferenczy, Alex; Castle, Philip E.

In: Journal of clinical microbiology, Vol. 52, No. 6, 01.01.2014, p. 2089-2095.

Research output: Contribution to journalArticle

Einstein, MH, Smith, KM, Davis, TE, Schmeler, KM, Ferris, DG, Savage, AH, Gray, JE, Stoler, MH, Wright, TC, Ferenczy, A & Castle, PE 2014, 'Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy', Journal of clinical microbiology, vol. 52, no. 6, pp. 2089-2095. https://doi.org/10.1128/JCM.00176-14
Einstein, Mark H. ; Smith, Katherine M. ; Davis, Thomas E. ; Schmeler, Kathleen M. ; Ferris, Daron Gale ; Savage, Ashlyn H. ; Gray, Jermaine E. ; Stoler, Mark H. ; Wright, Thomas C. ; Ferenczy, Alex ; Castle, Philip E. / Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. In: Journal of clinical microbiology. 2014 ; Vol. 52, No. 6. pp. 2089-2095.
@article{21a4dd5f4bc2450e81960eb1e6f7172b,
title = "Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy",
abstract = "High-risk human papillomavirus (hrHPV) testing is now being introduced as a potential primary screening test for improved detection of cervical precancer and cancer. Current U.S. Food and Drug Administration-approved tests are batch tests that take several hours to complete. A rapid, non-batch test might permit point-of-care (POC) testing, which can facilitate same-day screen and management strategies. For a non-batch, random-access platform (GeneXpert; Cepheid, Sunnyvale, CA), a prototype hrHPV assay (Xpert) has been developed where testing for 14 hrHPV types can be completed in 1 h. In the first clinical evaluation, Xpert was compared to two validated hrHPV tests, the cobas HPV test (cobas, Roche Molecular Systems) and Hybrid Capture 2 (hc2, Qiagen), and to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in the United States (n = 697). The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) (n = 141) was equal to that of cobas (90.8{\%} versus 90.8{\%}, P = 1) and greater than that of hc2 (90.8{\%} versus 81.6{\%}, P =0.004). Xpert was more specific than cobas (42.6{\%} versus 39.6{\%}, P = 0.02) and less specific than hc2 (42.6{\%} versus 47.7{\%}, P<0.001). Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CIN3+) (n = 91). HPV16 detection by Xpert identified 41.8{\%} of the CIN2+specimens with a positive predictive value (PPV) of 54.6{\%}. By comparison, HPV16 detection by cobas identified 42.6{\%} of the CIN2+specimens with a PPV of 55.0{\%}. hrHPV detection by the Xpert demonstrated excellent clinical performance for identifying women with CIN2+and CIN3+that was comparable to that of currently available clinically validated tests.",
author = "Einstein, {Mark H.} and Smith, {Katherine M.} and Davis, {Thomas E.} and Schmeler, {Kathleen M.} and Ferris, {Daron Gale} and Savage, {Ashlyn H.} and Gray, {Jermaine E.} and Stoler, {Mark H.} and Wright, {Thomas C.} and Alex Ferenczy and Castle, {Philip E.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/JCM.00176-14",
language = "English (US)",
volume = "52",
pages = "2089--2095",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy

AU - Einstein, Mark H.

AU - Smith, Katherine M.

AU - Davis, Thomas E.

AU - Schmeler, Kathleen M.

AU - Ferris, Daron Gale

AU - Savage, Ashlyn H.

AU - Gray, Jermaine E.

AU - Stoler, Mark H.

AU - Wright, Thomas C.

AU - Ferenczy, Alex

AU - Castle, Philip E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - High-risk human papillomavirus (hrHPV) testing is now being introduced as a potential primary screening test for improved detection of cervical precancer and cancer. Current U.S. Food and Drug Administration-approved tests are batch tests that take several hours to complete. A rapid, non-batch test might permit point-of-care (POC) testing, which can facilitate same-day screen and management strategies. For a non-batch, random-access platform (GeneXpert; Cepheid, Sunnyvale, CA), a prototype hrHPV assay (Xpert) has been developed where testing for 14 hrHPV types can be completed in 1 h. In the first clinical evaluation, Xpert was compared to two validated hrHPV tests, the cobas HPV test (cobas, Roche Molecular Systems) and Hybrid Capture 2 (hc2, Qiagen), and to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in the United States (n = 697). The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) (n = 141) was equal to that of cobas (90.8% versus 90.8%, P = 1) and greater than that of hc2 (90.8% versus 81.6%, P =0.004). Xpert was more specific than cobas (42.6% versus 39.6%, P = 0.02) and less specific than hc2 (42.6% versus 47.7%, P<0.001). Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CIN3+) (n = 91). HPV16 detection by Xpert identified 41.8% of the CIN2+specimens with a positive predictive value (PPV) of 54.6%. By comparison, HPV16 detection by cobas identified 42.6% of the CIN2+specimens with a PPV of 55.0%. hrHPV detection by the Xpert demonstrated excellent clinical performance for identifying women with CIN2+and CIN3+that was comparable to that of currently available clinically validated tests.

AB - High-risk human papillomavirus (hrHPV) testing is now being introduced as a potential primary screening test for improved detection of cervical precancer and cancer. Current U.S. Food and Drug Administration-approved tests are batch tests that take several hours to complete. A rapid, non-batch test might permit point-of-care (POC) testing, which can facilitate same-day screen and management strategies. For a non-batch, random-access platform (GeneXpert; Cepheid, Sunnyvale, CA), a prototype hrHPV assay (Xpert) has been developed where testing for 14 hrHPV types can be completed in 1 h. In the first clinical evaluation, Xpert was compared to two validated hrHPV tests, the cobas HPV test (cobas, Roche Molecular Systems) and Hybrid Capture 2 (hc2, Qiagen), and to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in the United States (n = 697). The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) (n = 141) was equal to that of cobas (90.8% versus 90.8%, P = 1) and greater than that of hc2 (90.8% versus 81.6%, P =0.004). Xpert was more specific than cobas (42.6% versus 39.6%, P = 0.02) and less specific than hc2 (42.6% versus 47.7%, P<0.001). Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CIN3+) (n = 91). HPV16 detection by Xpert identified 41.8% of the CIN2+specimens with a positive predictive value (PPV) of 54.6%. By comparison, HPV16 detection by cobas identified 42.6% of the CIN2+specimens with a PPV of 55.0%. hrHPV detection by the Xpert demonstrated excellent clinical performance for identifying women with CIN2+and CIN3+that was comparable to that of currently available clinically validated tests.

UR - http://www.scopus.com/inward/record.url?scp=84901649719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901649719&partnerID=8YFLogxK

U2 - 10.1128/JCM.00176-14

DO - 10.1128/JCM.00176-14

M3 - Article

C2 - 24719440

AN - SCOPUS:84901649719

VL - 52

SP - 2089

EP - 2095

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 6

ER -